News >

Schwartzberg Sheds Light on Rise of Biosimilars in Oncology

Brittany Cote
Published: Thursday, Feb 06, 2020

Lee S. Schwartzberg,

Lee S. Schwartzberg, MD
The additions of biosimilars for trastuzumab (Herceptin), bevacizumab (Avastin), and rituximab (Rituxan) to oncology have proven to be of significant value for patients across a number of tumor types, according to Lee Schwartzberg, MD, FACP.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication